 | Up a level |
Hertel, C; Cavelti, M; Lerch, S; Mürner-Lavanchy, I; Reichl, C; Koenig, J; Kaess, M (2024). Does personality dysfunction add incremental utility over general psychopathology when modeling previous suicide attempts in adolescent patients? Journal of affective disorders, 361, pp. 465-471. Elsevier 10.1016/j.jad.2024.06.038
Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Bühlmann, M; Fehr, M; Schönenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Müller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K; Swiss Group for Clinical Cancer Research, (SAKK) (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, 22(1), pp. 80-5. Oxford: Oxford University Press 10.1093/annonc/mdq319
D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2007). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of oncology, 19(4), pp. 739-745. Oxford: Oxford University Press 10.1093/annonc/mdm564
Mürner-Lavanchy, I; Koenig, J; Lerch, S; van der Venne, P; Höper, S; Resch, F; Kaess, M (22 June 2022). Neurocognition in adolescents who engage in non-suicidal self-injury (Unpublished). In: International Society for the Study of Self-Injury. online. 22.-24.06.22.
